Melasma: Current and future treatments

Expert Review of Dermatology

Volumn 3, Issue 2, 2008, Pages 187-193

  Berardesca, Enzo ^a   Ardigò, Marco ^a   Berardesca, Marta ^a   Cameli, Norma ^a  

^a SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

Author keywords

Chemical peel; Glycolic acid; Hydroquinone; Hyperpigmentation; Laser; Melanogenesis; Melasma; Retinoid; Treatment

Indexed keywords

ADAPALENE; ALPHA TOCOPHEROL; ASCORBIC ACID; AZELAIC ACID; CLOBETASOL; CLOBETASOL PROPIONATE; DEXAMETHASONE; FLUOCINOLONE ACETONIDE; GLYCOLIC ACID; HYDROQUINONE; ISOTRETINOIN; KOJIC ACID; LACTIC ACID; MONOBENZONE; PLACEBO; RETINOIC ACID; SALICYLIC ACID; SUNSCREEN;

BURNING SENSATION; CHLOASMA; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTACT DERMATITIS; CONTROLLED CLINICAL TRIAL; DERMATITIS; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DRY SKIN; ERYTHEMA; HUMAN; HYPERPIGMENTATION; INTENSE PULSED LIGHT; IONTOPHORESIS; IRRITANT DERMATITIS; LEUKODERMA; LOW LEVEL LASER THERAPY; MONOTHERAPY; NAIL DISEASE; OCHRONOSIS; PATIENT SAFETY; PHOTOTHERAPY; PIGMENT DISORDER; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SKIN ABRASION; TELANGIECTASIA;

EID: 55249100528     PISSN: 17469872     EISSN: None     Source Type: Journal    
DOI: 10.1586/17469872.3.2.187     Document Type: Review

References (44)

1. Pandya AG, Guevara IL. Disorders of hyperpigmentation. Dermatol. Clin. 18(1), 91-98 (2000).
2. Palumb A, Dischia M, Misuraca G. Mechanism of inhibition of melanogenesis by hydroquinone. Biochim. Biophys. Acta 1073, 85-90 (1991).
3. Ennes SBP, Paschoalick RC, Mota de Avelar Alchorne M. A double-blind, comparative, placebo-controlled study of the efficacy and tolerability of 4% hydroquinone as a depigmenting agent in melasma. J. Dermatolog. Treat. 11, 173-179 (2000).
4. Haddad AL, Maros LF, Brunstein F, Ferreira LM, Silva A, Costa D. A clinical, prospective, randomized, double-blind trial comparing skin whitening complex with hydroquinone vs. placebo in the treatment of melasma. Int. J. Dermatol. 42, 153-156 (2003).
5. Levin CY, Maibach H. Exogenous ochronosis. An update on clinical features, causative agents and treatment options. Am. J. Clin. Dermatol. 2, 213-217 (2001).
6. Kimbrough-Green CK, Griffiths CE, Finkel LJ. Topical retinoic acid (tretinoin) for melasma in black patients. Arch. Dermatol. 130, 727-733 (1994).
7. Griffiths CE, Finkel LJ, Ditre CM, Hamilton TA, Ellis CN, Voorhees JJ. Topical tretinoin (retinoic acid) improves melasma. A vehicle-controlled, clinical trial. Br. J. Dermatol. 129(4), 415-421 (1993).
8. Leenutaphong V, Nettakul A, Rattanasuwon P. Topical isotretinoin for melasma in Thai patients: a vehicle-controlled clinical trial. J. Med. Assoc. Thai. 82(9), 868-875 (1999).
9. Dogra S, Kanwar AJ, Parasad D. Adapalene in the treatment of melasma: a preliminary report. J. Dermatol. 29, 539-540 (2002).
10. Rigoni C, Toffolo P, Serri R, Caputo R. [Use of a cream based on 20% azelaic acid in the treatment of melasma]. G. Ital. Dermatol. Venereol. 124(1-2), I-VI (1989).
11. Verallo-Rowell VM, Verallo V, Graupe K, Lopez-Villafuerte L, Garcia-Lopez M. Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma. Acta. Derm. Venereol. Suppl (Stockholm) 143, 58-61 (1989).
12. Balina LM, Graupe K. The treatment of melasma. 20% azelaic acid versus 4% hydroquinone cream. Int. J. Dermatol. 30, 893-895 (1991).
13. Zaumseil R-P Graupe K. Topical azelaic acid in the treatment of melasma: pharmacological and clinical considerations. In: Melasma - New Approaches to Theraphy. Martin-Dunitz, London, UK 19-41 (1995).
14. Sarkar R, Bhalla M, Kanwar AJ. A comparative study of 20% azelaic acid cream monotherapy versus a sequential therapy in the treatment of melasma in dark-skinned patients. Dermatology 205, 249-254 (2002).
15. Huh C-H, Seo K-I, Park J-Y, Lim J-G, Fun H-C, Pak K-C. A randomized, double-blind, placebo-controlled trail of vitamin C iontophoresis in melasma. Dermatology 206, 316-320 (2003).
16. Yoshimura K, Harii K, Aoyama T, Iga T. Experience with a strong bleaching treatment for skin hyperpigmentation in Orientals. Plast. Reconstr. Surg. 105, 1097-1108 (2000).
17. Kauh YC, Zachian TF. Melasma. Adv. Exp. Med. Biol. 455, 491-499 (1999).
18. Grimes PE. A microsponge formulation of hydroquinone 4% and retinol 0.15% in the treatment of melasma and postinflammatory hyperpigmentation. Cutis 74(6), 362-368 (2004).
19. Guevara IL, Pandya AG. Safety and efficacy of 4% hydroquinone combined with 10% glycolic acid, antioxidants, and sunscreen in the treatment of melasma. Int. J. Dermatol. 42(12), 966-972 (2003).
20. Garcia A, Fulton JE. The combination of glycolic acid and hydroquinone or kojic acid for the treatment of melasma and related conditions. Dermatol. Surg. 22, 443-447 (1996).
21. Kligman AM, Willis I. A new formula for depigmenting human skin. Arch. Dermatol. 111, 40-48 (1975).
22. Taylor SC, Torok H, Jones T et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis 72, 67-72 (2003).
23. Maeda K, Naganura M. Topical trans-4- aminomethylcyclohexanecarboxylic (tranexamic acid) prevents ultraviolet radiation induced pigmentation. J. Photochem. Photobiol. B. Biol. 47, 130-141 (1998).
24. Lee JH, Park JG, Lim SH et al. Localized intradermal microinjection of tranexamic acid for treatment of melasma in Asian patients: a preliminary clinical trial. Dermatol. Surg. 32(5), 626-631 (2006).
25. Javaheri SM, Handa S, Kaur I, Kumar B. Safety and efficacy of glycolic acid facial peel in Indian women with melasma. Int. J. Dermatol. 40, 354-357 (2001).
26. Lawrence N, Cox SE, Brody HJ. Treatment of melasma with Jessner's solution versus glycolic acid: a comparison of clinical efficacy and evaluation of the predictive ability of Wood's light examination. J. Am. Acad. Dermatol. 36(4), 589-593 (1997).
27. Hurley ME, Guevara IL, Gonzales RM, Pandya AG. Efficacy of glycolic acid peels in the treatment of melasma. Arch. Dermatol. 138, 1578-1582 (2002).
28. Grimes PE. The safety and efficacy of salicylic acid chemical peels in darker racial - ethnic groups. Dermatol. Surg. 25(1), 18-22 (1999).
29. Cucé LC, Bertino MCM, Scattone LK, Birkenhauer MC. Tretinoin peeling. Dermatol. Surg. 27, 12-14 (2001).
30. Berardesca E, Cameli N, Primavera G, Carrera M. Clinical and instrumental evaluation ofskin improvement after treatment with a new 50% pyruvic acid peel. Dermatol. Surg. 32, 526-531 (2006).
31. Kopera D. Ruby laser treatment of melasma and postinflammatory hyperpigmentation. Dermatol. Surg. 21, 990-995 (1995).
32. 2 laser followed by Q-switched alexandrite laser: a pilot study. Dermatol. Surg. 25, 494-497 (1999).
33. 2 laser and Q-switched alexandrite laser compared with Q-switched alexandrite laser alone for refractory melasma: slit-faced design. Dermatol. Surg. 29, 59-64 (2003).
34. Lee G-Y, Kim H-J, Whang K-K. The effect of combination treatment of the recalcitrant pigmentary disorders with pigmented laser and chemical peel. Dermatol. Surg. 28, 1120-1123 (2002).
35. Manaloto RM, Alster T. Erbium:YAG laser resurfacing for refractory melasma. Dermatol. Surg. 25(2), 121-123 (1999).
36. Tannous ZS, Astner S. Utilizing fractional resurfacing in the treatment of therapy-resistant melasma. J. Cosmet. Laser Ther. 7, 39-43 (2005).
37. Rokhsar CK, Fitzpatrick RE. The treatment of melasma with fractional photothermolysis: a pilot study. Dermatol. Surg. 31, 1645-1650 (2005).
38. Moreno Arias GA, Ferrando J. Intense pulsed light for melanocytic lesions. Dermatol. Surg. 27, 397-400 (2001).
39. Wang CC, Hui CY, Sue YM, Wong WR, Hong HS. Intense pulsed light for the treatment of refractory melasma in Asian persons. Dermatol. Surg. 30, 1196-1200 (2004).
40. Kunachak S, Leelaudomlipi P, Wongwaisayawan S. Dermabrasion: a curative treatment for melasma. Aesthetic Plast. Surg. 25, 114-117 (2001).
41. Coimbra M, Rohric RJ, Chao J, Brown SA. A prospective controlled assessment of microdermabrasion for damaged skin and fine rhytides. Plast. Recostruct. Surg. 113, 1438-1443 (2004).
42. Spencer JM, Kurtz ES. Approaches to document the efficacy and safety of microdermabrasion procedure. Dermatol. Surg. 32, 1353-1357 (2006).
43. Rigopoulos D, Gregoriou S, Katsambas A. Hyperpigmentation and melasma. J. Cosmet. Dermatol. 6, 195-202 (2007).
44. Yang C-H, Shen S-C, Lee JC et al. Seeing the gene therapy: application of gene gun technique to transfect and decolour pigmented-rat skin with human agouti signalling protein cDNA. Gene Ther. 11(13), 1033-1039 (2004).